PMV Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Unaudited financial statements; amounts below are in U.S. dollars. PMV is a clinical-stage precision oncology company developing small-molecule therapies targeting p53. It has no approved products and has generated no revenue.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $11.5 million | $7.7 million | $23.3 million | $15.2 million |
| General and administrative expense | $6.4 million | $5.4 million | $13.2 million | $9.6 million |
| Net loss | $17.3 million | $12.9 million | $35.7 million | $24.5 million |
| Basic and diluted loss per share | $0.38 | $0.29 | $0.79 | $0.54 |
| Operating cash used | Not separately reported by quarter | $31.7 million | $22.1 million |
- At June 30, cash, cash equivalents and marketable securities totaled $277.4 million, down from $314.1 million at December 31, 2021. Restricted cash was an additional $0.8 million.
- Working capital was $270.5 million. Total liabilities were $23.6 million, including $12.6 million of operating lease liabilities. The filing reports no borrowings or other financial debt.
- Six-month investing cash outflow was $54.1 million, primarily reflecting net purchases of marketable securities and $4.3 million of property and equipment. Financing cash inflow was $0.4 million, mainly from option exercises and employee stock purchases.
- Profitability and operating margins are not meaningful because the company has no revenue and is operating at a loss.
Changes versus prior comparable periods
- Q2 operating expenses increased $4.8 million year over year; six-month expenses rose $11.8 million. Increased PC14586 clinical-development spending and personnel costs were the principal drivers.
- Research and development expense increased $3.8 million in Q2 and $8.1 million for the six months, mainly as PC14586 advanced through its Phase 1/2 trial. General and administrative expense increased $1.0 million in Q2 and $3.6 million for the six months, reflecting headcount, public-company support and facilities.
- Six-month net loss widened by $11.3 million year over year. Interest income increased, partly offsetting the higher operating loss.
- Cash used in operations rose to $31.7 million from $22.1 million. Total financial assets declined $36.6 million from year-end; the cash balance fell as funds were shifted into marketable securities and used to fund operations and investment.
Outlook, risks and notable items
- Management said June 30 cash, cash equivalents and marketable securities were expected to fund operations at least through 2023; it also cautioned that this estimate depends on assumptions and capital could be used sooner. The company expects increased investment through the remainder of 2022 and 2023 and substantial losses for the foreseeable future.
- Management expects no product-sales revenue in the foreseeable future. Additional financing may be required; equity financing could dilute shareholders, while debt or partnering could impose obligations or require relinquishing rights.
- PC14586 is in a Phase 1/2 trial and received FDA Fast Track Designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation. Initial Phase 1 clinical data were presented in June 2022. The filing provides no quantitative clinical results in the supplied text.
- The company is relocating its headquarters and laboratory operations to a new Princeton facility under a lease extending through 2032. The lease has $12.6 million of recorded liabilities; future minimum payments, net of reimbursements, were reported as $17.3 million.
- Key risks include clinical and regulatory uncertainty, funding needs, competition, dependence on third-party research and manufacturing providers, intellectual-property protection, and potential operational disruption from COVID-19 and supply-chain conditions. No material change to previously disclosed risk factors was reported; no material litigation was identified.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2022. No material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether subsequent PC14586 trial updates support the development timeline and potential regulatory strategy.
- Whether actual cash burn, planned clinical spending and facility costs remain consistent with management’s runway estimate through 2023.
- Any financing, collaboration or licensing plans, and their potential dilution or impact on program rights.
- The composition, maturities and valuation sensitivity of the marketable-securities portfolio, including unrealized losses.
- Progress and costs associated with the Princeton facility move and the company’s long-term lease commitments.